Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, levodopa (Inbrija®) cannot be endorsed for use within NHS Wales for the intermittent treatment of episodic motor fluctuations (off episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor. Levodopa (Inbrija®) is being considered for suitability for AWMSG assessment by the AWMSG Scrutiny Panel at their meeting on 09/07/2026. |
||
|
||
Medicine details |
||
| Medicine name | levodopa (Inbrija®) | |
| Formulation | 33 mg inhalation powder, hard capsule | |
| Reference number | 2719 | |
| Indication | For the intermittent treatment of episodic motor fluctuations (off episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor |
|
| Company | Acorda Therapeutics Inc | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Scrutiny Panel meeting date | 09/07/2026 | |
| Date of issue | 16/06/2020 | |
| Further information Levodopa (Inbrija®) is being considered for suitability for AWMSG assessment by the AWMSG Scrutiny Panel at their meeting on 09/07/2026. |
||